ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the effects (good and bad) of
ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that
is thought to work by interfering with the ability of cancer cells to grow and divide. It is
a part of a group of drugs called "epothilones" which appear to cause shrinkage of cancer in
some patients with breast cancer. It is generally difficult for chemotherapy to enter the
brain. However, it is believed that ZK219477 crosses into the brain. We are also studying
whether an investigational MRI scan procedure may eventually help to predict which patients
will benefit from ZK219477.
Phase:
Phase 2
Details
Lead Sponsor:
Nancy Lin, MD
Collaborators:
Bayer Breast Cancer Research Foundation Brigham and Women's Hospital